New HIV drug patent pool “offers hope to millions”BMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b5557 (Published 21 December 2009) Cite this as: BMJ 2009;339:b5557
- Peter Moszynski
An innovative approach to expanding access to newly developed and potential future HIV drugs has been launched by way of a new patent pool by the international health financing agency, UNITAID. Sharing patents through the pool should help to reduce drug prices by allowing pharmaceutical companies to share new formulations in exchange for receiving royalties for their research and development.
Phillipe Douste-Blazy, chair of UNITAID, said the pool “represents an additional tool to increase access to HIV treatment, and an opportunity for patent holders to voluntarily contribute to the attainment of crucial health related goals endorsed by the international community.”
He said that his agency had consulted widely with a “variety of stakeholders” from communities living with …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial